Frankfurt
12.12.25 | 08:07
0,178 Euro
-0,56 % -0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IRLAB Therapeutics: The European Patent Office Intends to Grant a New Patent for IRLAB's Mesdopetam | 201 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / December 11, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's... ► Artikel lesen | |
| 27.11. | IRLAB Therapeutics: IRLAB Participates in Redeye Technology & Life Science Day on December 3, 2025 | 224 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / November 27, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 20.11. | IRLAB Therapeutics: Nomination Committee Appointed for IRLAB's Annual General Meeting 2026 | 241 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / November 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that... ► Artikel lesen | |
| 07.11. | IRLAB Therapeutics: IRLAB Receives Acceptance for Two Abstracts at AD/PD 2026: The 20th International Conference on Alzheimer's and Parkinson's Diseases | 296 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / November 7, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 29.10. | IRLAB Therapeutics: IRLAB Publishes Interim Report for The Period January - September 2025 | 364 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 29, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| 23.10. | IRLAB Therapeutics: IRLAB: Invitation To The Interim Report For Q3 2025 Presentation And Webcast | 263 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's... ► Artikel lesen | |
| 09.10. | IRLAB Therapeutics: IRLAB Appoints Gustaf Albèrt as the New Chief Financial Officer | 294 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / October 9, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that... ► Artikel lesen | |
| IRLAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.10. | IRLAB Therapeutics: IRLAB to Present at Redeye Theme: Neurology | 226 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 9, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments... ► Artikel lesen | |
| 02.10. | IRLAB Therapeutics: IRLAB Progresses Fully Funded IRL757 Study in Parkinson's Disease in Partnership with MSRD | 329 | ACCESS Newswire | ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / October 2, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg... ► Artikel lesen | |
| 04.09. | IRLAB Therapeutics: IRLAB Is Granted a Patent Strengthening the Market Exclusivity of The Drug Candidate Mesdopetam in China | 321 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / September 4, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced... ► Artikel lesen | |
| 29.08. | Change in Number of Shares and Votes in IRLAB Therapeutics AB | 322 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 29, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - During August 2025, the registered number of shares and votes in IRLAB Therapeutics AB ("IRLAB") has... ► Artikel lesen | |
| 27.08. | IRLAB Therapeutics: IRLAB Publishes Interim Report for the Period January - June 2025 | 386 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 27, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced... ► Artikel lesen | |
| 22.08. | IRLAB Therapeutics: IRLAB: Invitation to The Interim Report for Q2 2025 Presentation and Webcast | 361 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 22, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced... ► Artikel lesen | |
| 21.08. | IRLAB Therapeutics: IRLAB Appoints Roy Jonebrant as Interim CFO | 342 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 21, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced... ► Artikel lesen | |
| 11.08. | IRLAB Therapeutics: IRLAB's CFO Viktor Siewertz Leaves the Company for a New Leading Position | 439 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 11, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announces... ► Artikel lesen | |
| 30.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 30.06.2025 | 1.930 | Xetra Newsboard | Das Instrument EMH DE000A2YN777 PFERDEWETTEN.DE AG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 30.06.2025 und ex Kapitalmassnahme am 01.07.2025 The instrument EMH DE000A2YN777 PFERDEWETTEN.DE... ► Artikel lesen | |
| 24.06. | IRLAB Therapeutics AB: The Board of Directors of IRLAB has resolved on an 85 per cent secured rights issue of approximately SEK 136 million and receives extended debt financing of SEK 30 million | 270 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE... ► Artikel lesen | |
| 11.06. | Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB | 431 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 11, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Today, on Wednesday June 11, 2025, IRLAB Therapeutics AB held its Annual General Meeting.The following... ► Artikel lesen | |
| 04.06. | IRLAB Therapeutics: IRLAB Participates in Aktiespararna's Event - Aktiedagarna | 354 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 4, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, June 4, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering... ► Artikel lesen | |
| 28.05. | IRLAB Therapeutics: IRLAB Reports Positive Results from the Second Part of a Phase I Study with IRL757 | 707 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 36,500 | +0,47 % | Verkehrte Welt im DAX: Bayer Top, Rheinmetall Flop | Bayer feiert ein spektakuläres Comeback an der Börse, während die Aktie von Rheinmetall überraschend Federn lassen musste. Trotz der Kursverluste bleibt der Rüstungskonzern aber weiterhin ein Favorit... ► Artikel lesen | |
| MERCK KGAA | 117,85 | -1,05 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Merck KGaA von 155 auf 150 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Die Papiere der Darmstädter blieben unterbewertet... ► Artikel lesen | |
| NOVO NORDISK | 42,840 | +0,07 % | Bei Bayer kehrt die Hoffnung zurück, Novo Nordisk kämpft mit noch mehr Konkurrenz, Eli Lilly dreht an der Preisschraube und BioNTech meldet Studienerfolg | Die ansonsten stets vielbeachteten Pharma-Aktien standen in diesem Jahr ein wenig im Schatten von KI und Rüstung, doch langweilig wurde es im Segment dennoch nur selten. Zum Jahresende scheinen sich... ► Artikel lesen | |
| HARROW | 47,060 | -7,91 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| CANOPY GROWTH | 1,460 | -2,41 % | Berauschende Überlegungen: Cannabis-Aktien wie Tilray, Green Thumb oder Canopy Growth springen hoch | Gedankenspiele in den USA, die Klassifizierung von Marihuana zu ändern und die Substanz so als weniger gefährlich einzustufen, sorgen vor dem Wochenende für Euphorie an der Börse. Der Schritt könnte... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 2,405 | -18,47 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| TILRAY BRANDS | 10,200 | 0,00 % | Opening Bell: Eli Lilly, Broadcom, Planet Labs, Tilray, Citigroup, JPMorgan, Amazon, Nvidia | Die US-Börsen haben am Donnerstag uneinheitlich geschlossen. Der Dow Jones legte deutlich zu, markierte bei 48.756,34 Punkten ein neues Rekordhoch und beendete den Handel 1,34 Prozent höher. Der Nasdaq... ► Artikel lesen | |
| SCHOTT PHARMA | 15,140 | +0,26 % | Friedrich Vorwerk Aktie: Allzeithoch voraus? - Deutsche Bank, energenta, Hensoldt, HMS Bergbau und Schott Pharma im Marktbericht | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 6,210 | -1,74 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| ELI LILLY | 873,60 | -0,21 % | Lilly Reports Positive Phase 3 EMBER-3 Results For Inluriyo In Advanced Breast Cancer | INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced updated results from the Phase 3 EMBER-3 study evaluating Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients... ► Artikel lesen | |
| MERCK & CO | 85,40 | -0,12 % | Merck & Co., Inc.: Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) | Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the... ► Artikel lesen | |
| PFIZER | 21,975 | -0,23 % | Angriff auf den Kraftstoff der Tumore: Warum Roche, Pfizer und Vidac Pharma die Onkologie neu definieren | In der modernen Krebstherapie geht es nicht mehr um den brachialen Angriff, sondern um präzise Eingriffe. Während die Onkologie der letzten Jahrzehnte von unspezifischen Zellgiften dominiert wurde,... ► Artikel lesen | |
| AURORA CANNABIS | 4,630 | +0,11 % | Why Aurora Cannabis Stock Just Rocketed Higher | ||
| ETON PHARMACEUTICALS | 16,700 | -1,07 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| ASTRAZENECA | 153,10 | -1,38 % | JPMORGAN stuft ASTRAZENECA auf 'Positiv' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Astrazeneca von 14000 auf 16000 Pence angehoben und die Einstufung auf "Overweight" belassen. Analyst Richard Vosser setzte die... ► Artikel lesen |
IRLAB THERAPEUTICS AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,001 (-0,56 %) liegt der Kurs bei 0,178 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IRLAB THERAPEUTICS AB finden Sie auf Wallstreet Online.